Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK2 | Q16620 | 4/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13869078 | 0.88 | NTRK1 (0.51) | NTRK2NTRK1CSNK2A2CSNK2A1PBRM1 | |
| SCHEMBL12537733 | 0.82 | NTRK1 (0.53) | NTRK2NTRK1CSNK2A2CSNK2A1PBRM1 | |
| SCHEMBL13869055 | 0.82 | MAPK14 (0.47) | NTRK2NTRK1CSNK2A2CSNK2A1PBRM1 | |
| SCHEMBL12537701 | 0.82 | NTRK2 (0.55) | NTRK2NTRK1CSNK2A2CSNK2A1 | |
| SCHEMBL13885180 | 0.80 | NTRK2 (0.83) | NTRK2NTRK1NPC1LMNA | |
| SCHEMBL12537481 | 0.80 | NTRK1 (0.51) | NTRK2NTRK1CSNK2A2CSNK2A1PBRM1 | |
| SCHEMBL12537587 | 0.79 | NTRK1 (0.73) | NTRK2NTRK1CSNK2A2CSNK2A1PBRM1 | |
| SCHEMBL12537729 | 0.77 | NTRK1 (0.48) | NTRK2NTRK1CSNK2A2CSNK2A1PBRM1 | |
| SCHEMBL12537487 | 0.76 | NTRK2 (0.55) | NTRK2NTRK1CSNK2A2CSNK2A1PIK3CD | |
| SCHEMBL14537224 | 0.76 | CSNK2A2 (0.43) | NTRK2NTRK1CSNK2A2CSNK2A1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948664-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| WO-2007061882-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | NTRK2 1/4885NTRK1 3/4885CSNK2A2 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.